

July 26, 2013

«First__Name» «Last__Name», «Title»
 «Address__1»
 «Address__2»
 «City», «State» «Zip»

Re: HEDIS® Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis

Dear «First__Name» «Last__Name», «Title»:

We know that you are an invaluable medical professional who strives to provide the highest quality of care to your patients. We are sending this letter as a part of our continued efforts to ensure that you are aware of Jai Medical Systems Managed Care Organization, Inc.'s quality assurance standards as they relate to HEDIS® (Healthcare Effectiveness Data and Information Set). It is our hope that this information will assist you in achieving our quality assurance goals.

The **Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis** measure evaluates whether adults 18 years of age and older who have been diagnosed twice with rheumatoid arthritis within the measurement year were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).


As the PCP of the member diagnosed with rheumatoid arthritis, we understand that you may refer your patient to a specialist instead of prescribing this medication yourself. It is important to work together with the specialist and follow up with the patients to ensure they are receiving the appropriate medications to manage their rheumatoid arthritis. The following table of DMARDs are supplied in the HEDIS® criteria for your reference:

Description	Prescription			J Codes
5-Aminosalicylates	• Sulfasalazine			
Alkylating agents	• Cyclophosphamide			
Aminoquinolines	• Hydroxychloroquine			
Anti-rheumatics	• Auranofin • Gold sodium thiomalate	• Leflunomide • Methotrexate	• Penicillamine	J1600, J9250, J9260
Immunomodulators	• Abatacept • Adalimumab • Anakinra • Certolizumab	• Certolizumab pegol • Etanercept • Golimumab	• Infliximab • Rituximab • Tocilizumab	J0129, J0135, J0718, J1438, J1745, J9310
Immunosuppressive agents	• Azathioprine	• Cyclosporine	• Mycophenolate	J7502, J7515, J7516, J7517, J7518
Tetracyclines	• Minocycline			

Attached you will find a criteria receipt. After reviewing the standards for this measure, please sign and fax this receipt to Stephanie Scharpf at (410) 433-4615.


We believe that the information provided will help you understand how HEDIS® will be used to interpret the quality of care provided to our members. Please remember that this information has been adapted from HEDIS® guidelines and should not be substituted for your sound medical judgment. Thank you for your continued efforts to ensure that our members receive the highest quality of care possible. Please feel free to contact us at (410) 433-2200 if you have any questions or concerns.

Sincerely,



Frances Bird, M.D.
Director, Quality Assurance

Sincerely,



Stephanie Scharpf
Director, Regulatory Compliance and
Administration